New asthma drug shows promise in early trial
NCT ID NCT05018299
First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 2 times
Summary
This study tests a new medicine called FB704A in adults with severe asthma. The goal is to see if it is safe and can help control asthma symptoms. About 20 people will receive either the drug or a placebo over 8 weeks, with follow-up for 12 more weeks.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEVERE ASTHMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
China Medical University Hospital
Taichung, Taiwan
-
Kaohsiung Chang Gung Memorial Hospital
Kaohsiung City, Taiwan
-
National Taiwan University Hospital
Taipei, Taiwan
-
Taichung Veterans General Hospital
Taichung, Taiwan
-
Taipei Medical University Hospital
Taipei, Taiwan
-
Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare
Taipei, Taiwan
-
Taipei Municipal Wanfang Hospital
Taipei, Taiwan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a single injection tame severe asthma in fungal allergy?
- Could a simple exercise programme boost asthma remission?
- A two-step strategy: biologic drug may pave the way for immunotherapy in severe olive pollen asthma
- Could a biologic drug free severe asthma patients from High-Dose steroids?
- Scientists probe why tezepelumab doesn't stop all asthma attacks
- Smart inhalers track Fasenra's asthma control over full dosing cycle